Zymogen Activation and Subcellular Activity of Subtilisin Kexin Isozyme 1/Site 1 Protease

Journal of Biological Chemistry - United States
doi 10.1074/jbc.m114.588525
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Biochemistry & Molecular Biology (ASBMB)

Related search

PCSK6 (Proprotein Convertase Subtilisin/Kexin Type 6)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2017English

Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Clinical Research in Cardiology Supplements
Nuclear MedicineRadiologyMolecular BiologyStructural BiologyImagingMedicine
2019English

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), Soluble Lectin-Like Oxidized LDL Receptor 1 (SLOX-1) and Ankle Brachial Index in Short Term Overt Hypothyroidism

Endocrine Abstracts
2015English

Zymogen Activation as a Sensitive Enzymeamplifying Assay for a Protease With Tryptic Specificity

Biochemical Journal
1970English

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), Soluble Lectin-Like Oxidized LDL Receptor 1 (sLOX-1) and Ankle Brachial Index in Patients With Differentiated Thyroid Cancer

Endocrine Journal
EndocrinologyMetabolismDiabetes
2015English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke

Circulation. Genomic and precision medicine
GeneticsCardiovascular MedicineCardiology
2018English

Directional and Balancing Selection on Proprotein Convertase Subtilisin/Kexin Type 6 (PCSK6)

2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy